Drug intelligence / Profile preview

INR303

Development stage: Unknown
Lead developer: Imnewrun Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

INR303 is a monoclonal antibody developed by Imnewrun Biosciences. It acts as an inhibitor of programmed death-ligand 1 (PDL1), targeting the PDL1 protein to modulate immune responses. The drug is being investigated for its potential use in nerve degeneration and possibly other diseases, but it remains in the discovery phase with no clinical trial data or approvals reported as of April 2025[1].

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on INR303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INR303.

Explore the full profile